Kc Lam - Institute of Chinese Medicine, Chinese University of Hong Kong

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 29 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

Molly S C Li,Kirsty W C Lee,Kevin K S Mok,Herbert H F Loong,K C Lam, Florence S T Mok,Landon L Chan,Y M Lau, K P Chan, Joyce T Y Ng, Wesley K Y Wong, Benjamin H W Lam,

JTO clinical and research reportsno. 4 (2024): 100648-100648

引用0浏览0WOS引用

Brief Report: Risk of Recurrent Interstitial Lung Disease (ILD) from Osimertinib versus Erlotinib Rechallenge after Symptomatic Osimertinib-induced ILD

Molly SC. Li,Kirsty WC. Lee, Kevin KS. Mok,Herbert HF. Loong,K.C. Lam,Florence ST. Mok,Landon L. Chan,Y.M. Lau, K.P. Chan,Joyce TY. Ng, Wesley KY. Wong, Benjamin HW. Lam,

JTO Clinical and Research Reportspp.100648, (2024)

引用0浏览0引用

1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases

M. Li, K. Mok, L.L. Chan,K.W.C. Lee,H.H.F. Loong,K.C. Lam, F. Mok,Y.M. Lau, O. Chen, J. Ng,B. Lam, A. Chen,

Annals of Oncology (2023): S776-S777

引用0浏览0引用

Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib

M. S. C. Li, K. Mok, G. Tsui,K. W. C. Lee,K. C. Lam,H. H. F. Loong, F. Mok, L. L. Chan, K. Yan,T. Y. J. Ng, D. Johnson,B. Lam,

ANNALS OF ONCOLOGY (2023): S1690-S1690

引用0浏览0引用

Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD

M. S. Li,K. W. C. Lee,H. H. F. Loong,K. C. Lam,F. S. T. Mok,Y. M. Lau, K. P. Chan,K. K. S. Mok,J. T. Y. Ng, A. C. C. Chen, W. K. Y. Wong, B. H. W. Lam,

Journal of Thoracic Oncologyno. 11 (2023): S342-S342

引用0浏览0引用

Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme

O.S.H. Chan,V.H.F. Lee,S.F. Nyaw,M.T.Y. Kam,K.W.C. Lee,K.C. Lam

Clinical Oncology（2021）

引用0浏览0WOS引用

MA16.02 T790M Allelic Fraction Level Did Not Correlate Survival in T790M Positive NSCLC – Observations from an Early Access Program

O.S.H. Chan,K.C. Lam,V. Lee,S.F. Nyaw,M.W.R. Yeung

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis

Y. Wu,H. Tu,J. Feng,M. Shi, J. Zhao,Y. Wang, J. Chang, J. Wang,Y. Cheng,J. Zhu,E. Tan, Y. Zhang,

JOURNAL OF THORACIC ONCOLOGY（2019）

引用7浏览0引用

P1.01-98 A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions

Yi-Long Wu,Hai-Yan Tu,Jifeng Feng,M. Shi, J. Zhao, Yan Wang,Jianhua Chang,Jun Wang, Ying Cheng,J. Zhu,E. Tan,K. Li,

JOURNAL OF THORACIC ONCOLOGY（2018）

引用3浏览0引用

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

Yl Wu,H Tu,J Feng,M Shi, J Zhao, Y Wang, J Chang, J Wang,Y Cheng,J Zhu,Eh Tan,K Li,

JOURNAL OF THORACIC ONCOLOGY（2017）

引用9浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn